Peer-Reviewed Study Shows PRP Cuts Tumor Weight 86% in Pancreatic Model
PPCB is trading near its 52-week low of $0.41 (6.4% above the low) on light trading volume (0.2× avg).
Summary
Propanc published a peer-reviewed pilot study in Scientific Reports detailing PRP's anti-tumor effects. In an orthotopic pancreatic model, daily IV PRP reduced mean tumor weight by 85.9%; in ovarian, ~50%. The study also showed anti-angiogenic, anti-metastatic, and EMT-reversal activity across 24 cell lines. Clinical data from 46 advanced cancer patients via UK Specials Scheme showed mean survival of 9.0 months vs 5.6 expected (p<0.05). This follows the August 6 announcement of >90% tumor growth inhibition, but adds peer-reviewed validation and detailed mechanistic data. The company plans a Phase 1b trial in Q1 2027.
At the time of this announcement, PPCB was trading at $0.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.41 to $47.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.